HUTCHMED (00013): Announces Preclinical Data for HMPL-A830 at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

date
19/11/2026
Zhitong Finance APP news, HUTCHMED (00013) announced that preclinical data for HMPL-A830 were presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held in Barcelona, Spain, from November 18 to 20, 2026. HMPL-A830 is a globally first-in-class antibody-targeted conjugate drug (ATTC) candidate, composed of a highly selective and potent KRAS small molecule inhibitor as the payload, conjugated to an anti-epidermal growth factor receptor (EGFR) antibody.